we are missing the change in eGFR within the <60 eGFR cohort of the BETonMACE study.  Specifically, the relative change between those receiving standard of care/placebo and those receiving apabetalone.  No change??? maybe, but unlikely in my uneducated humble opinion.  How else would one explain a 50% RRR of MACE for those receiving apabetalone versus those on standard of care/placebo